Company Overview

Stereotaxis, Inc. is a medical technology company that designs, manufactures, and markets robotic systems for minimally invasive endovascular and electrophysiology procedures. The company operates within the medical robotics, cardiac electrophysiology, and interventional healthcare technology industries, focusing on improving precision, safety, and physician control during complex catheter-based procedures. Its core customers are hospitals and specialized cardiac centers performing catheter ablation procedures for cardiac arrhythmias.

The company’s primary revenue drivers are its robotic navigation platforms, proprietary software, and associated disposable devices used in electrophysiology labs. Stereotaxis is positioned as a differentiated provider through its use of magnetic navigation, which enables precise control of catheters while reducing radiation exposure and physical strain on physicians. Founded in the mid-1990s, the company initially explored medical imaging technologies before evolving into a focused developer of robotic magnetic navigation systems, culminating in its current emphasis on next-generation robotic platforms for cardiac interventions.

Business Operations

Stereotaxis operates as a single-reportable business segment centered on robotic navigation systems for endovascular procedures. Its flagship technologies include the Niobe® Magnetic Navigation System and the newer Genesis® Robotic Magnetic Navigation Platform, along with proprietary software and compatible catheter solutions. Revenue is generated through system sales, recurring software and service contracts, and the sale of disposable products used in procedures.

The company conducts operations in both domestic and international markets, with installations in hospitals across North America, Europe, and Asia. Stereotaxis controls its core intellectual property related to magnetic navigation, robotic control, and procedural software. Public disclosures indicate limited reliance on joint ventures, with growth primarily driven by direct sales, hospital relationships, and long-term service agreements. Information on certain subsidiaries and minor partnerships is limited; data inconclusive based on available public sources.

Strategic Position & Investments

Strategically, Stereotaxis is focused on expanding adoption of robotic-assisted electrophysiology by advancing automation, procedural efficiency, and remote navigation capabilities. Growth initiatives emphasize the global rollout of the Genesis® platform, expansion of compatible catheter technologies, and continued investment in software enhancements that support complex ablation workflows.

The company has historically pursued selective technology acquisitions and internal development rather than large-scale consolidation. Investments are concentrated in robotic automation, digital integration of electrophysiology labs, and physician workflow optimization. While Stereotaxis has referenced ongoing evaluation of adjacent robotic and endovascular applications, details on material acquisitions or external portfolio investments remain limited; data inconclusive based on available public sources.

Geographic Footprint

Stereotaxis is headquartered in North America (St. Louis, Missouri) and maintains a global commercial and service presence. Its robotic systems are installed in major healthcare institutions across Europe, Asia-Pacific, and selected markets in the Middle East and Latin America, reflecting a diversified international customer base.

The company’s international operations include direct sales, distributors, and service infrastructure supporting installed systems outside the United States. Europe represents a particularly significant market due to early adoption of magnetic navigation technology, while Asia-Pacific is viewed as a long-term growth region driven by increasing demand for advanced cardiac care.

Leadership & Governance

Stereotaxis was founded by David Fischel, who has played a central role in shaping the company’s technology-driven strategy and long-term vision. Leadership emphasizes clinical precision, physician-centric design, and the advancement of robotic automation in interventional medicine. The governance structure aligns executive compensation and strategic priorities with long-term adoption of its robotic platforms.

Key executives include:

• David Fischel – Chief Executive Officer and Chairman
• Thomas Younge – Chief Financial Officer

The leadership team’s strategic vision centers on expanding robotic adoption in electrophysiology through innovation, operational discipline, and global market penetration.